TP53 and breast cancer: Huang and associates validated this hypothesis by demonstrating that the loss of the Farnesoid X Receptor (FXR) leads to p53 acetylation in a CREB Binding Protein (CBP)-dependent manner, consequently initiating ferroptosis and constraining breast cancer proliferation and metastasis [79].